Vega NCT, Vega SDC, Arenas R

Language: Spanish
References: 17
Page: 111-114
PDF size: 189.65 Kb.

ABSTRACT

Background: chronic renal failure presents systemic repercussions and changes, presenting alterations at the nail, that can be secondary to non-infectious and infectious processes such as onychomycosis.
Objective: to determine the frequency of onychomycosis in patients with chronic kidney disease undergoing renal function replacement therapy by peritoneal dialysis.
Material and methods: descriptive, prospective and, cross-sectional study in patients with chronic kidney disease, on peritoneal dialysis, with suspicion of nail alteration
Results: 10 patients with nail involvement were studied, with a predominance in females, with an average age of 57.6 years, all were in peritoneal dialysis management with an average treatment of 3.5 years. Five presented positive direct examination for filaments, with negative culture in all the patients.
Conclusion: the prevalence of onychopathies in patients with kidney disease is high, mainly onychomycosis. We suggest that specialists should be aware of this infection.

REFERENCES

1. Zoccali C, Vanholder R, Massy Z et al., The systemic nature ofckd, Nat Rev Nephrol 2017; 13(6):344-58.

2. Ali Shafiee MA, Akbarian F, Memon KK et al., Dermatologicmanifestations in end-stage renal disease, Iranian Journal ofKidney Diseases 2015; 9:339-53.

3. Kidney Disease: Improving Global Outcomes (kdigo), ckd WorkGroup, kdigo 2012 clinical practice guideline for the evaluationand management of chronic kidney disease, Kidney Int Suppl2013; 3:1-150.

4. Stanifer J, Muiru A, Jafar T et al., Chronic kidney disease in lowandmiddle-income countries, Nephrol Dial Transplant 2016;31:868-74.

5. Ene-Iordache B, Perico N, Bikbov B, Carminati S et al., Chronickidney disease and cardiovascular risk in six regions of theworld (isn-kddc): a cross-sectional study, Lancet Glob Health2016; 4:e307-19.

6. Pérez-Terrazas H, Treviño-Becerra A y Cervantes-Hernández J,The blueprint of the Mexican Official Norm for peritoneal dialysis,Nefrología Mexicana 2002; 23:69-72.

7. Krop J, Coresh J, Chambless L et al., A community-based studyof explanatory factors for the excess risk for early renal functiondecline in blacks vs whites with diabetes: the atherosclerosisrisk in communities study, Arch Intern Med 1999; 159:1777-83.

8. Saran R, Robinson B, Abbott KC, Agodoa LY et al., US RenalData System 2016 Annual Data Report: epidemiology of kidneydisease in the United States, Am J Kidney Dis 2017; 69(Suppl.1):A7-8

9. Shimoyama H, Kuwano Y y Sei Y, Retrospective survey of treatmentoutcomes of efinaconazole 10% solution and luliconazole5% solution for onychomycosis in our facility, Med Mycol J2019; 60:95-100.

10. González L, Monteagudo B, Mosquera A et al., Onicomicosissubungueal proximal en paciente tratado con inhibidores delfactor de necrosis tumoral alfa, Semergen 2017; 43:245-6.

11. Gupta A, Stec N, Summerbell R et al., Onychomycosis: a review,J Eur Acad Dermatol Venereol 2020.

12. Chauhan S, D’Cruz S, Singh R y Sachdev A, A Mees’ lines, Lancet2008; 18:372 (9647)1410.

13. Short N y Shah C, Muehrcke’s lines, Am J Med 2010; 123:991-2.

14. Lin CJ, Wu CJ, Chen YC y Chen HH, Half and half nail secondaryto chronic renal failure, South Med J 2009; 102:1189-90.

15. Sandoval C, Gutiérrez M, Fernández R et al., Onicomicosis: incidenciaen pacientes con insuficiencia renal crónica y hemodiálisis,dcmq 2014; 12(3):172-4.

16. Arenas R, Micología médica ilustrada, 5ª ed., México, McGrawHill, 2014, p. 67.

17. Chang P y Rodas AC, Onicopatías en pacientes con insuficienciarenal, dcmq 2009; 7(2):91-7.